Sign inJoin free

Watch / Company News

Osteopore eyeing global expansion

17 July 20245:53

Osteopore eyeing global expansion

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key points:

  • Osteopore (ASX: OSX) signs exclusive distribution deal with leading medical device player, Zimmer Biomet (NYSE: ZBH)

  • Yujing Lim explores Osteopore's continuance in looking for expansion opportunities and speeding up growth in their four business areas

  • Osteopore eyes expansion into European, Middle East, and African markets through Zimmer agreement

Osteopore sealed an exclusive distribution agreement with Zimmer Biomet to distribute craniofacial products in 24 countries. CEO, Yujing Lim, shares that Zimmer is a leading medical device player with around 18,000 employees globally. Yujing expresses optimism over the partnership, viewing it as a significant stepping stone towards further commercialisation of Osteopore's craniofacial products.

The CEO of Osteopore (ASX: OSX) acknowledges the exclusivity of the deal but emphasised that the company is constantly on the lookout for opportunities to expand and accelerate growth, in addition to the company's confidence in the potential of their technology and products. Yujing also confirms that the technology is primarily for craniofacial reconstruction, including neurosurgical applications and plastic surgery applications.

Additionally, Yujing discusses Osteopore’s four business areas: craniofacial reconstruction, aesthetics, dental, and orthopedic applications. He reports steady progression in the orthopedics and talks about the company's growth trend as they observed a roughly 5% quarter on quarter growth for five consecutive quarters. Also revealed is Osteopore's focus on the European, Middle East, and African markets, along with Australia and New Zealand, leveraging their agreement with Zimmer.

Full unedited transcript below:

0:00

Osteopore (ASX: OSX) has inked an exclusive distribution deal with Zimmer Biomet to distribute craniofacial products in 24 countries in the early stages of distribution. Let's get the details. Osteopathy CEO Eugene Lim joins me now. Hi. Welcome back to office. Thank you so much for joining us. So I think we should start with who Zimmer Biomet is. Where do they operate so we can get some sort of a context for this conversation? Sure. Good afternoon, and thank you very much for inviting me on the show. Um, Zimmer is a fairly well known medical device player, uh, from a global perspective. They are ranked top 20. They are very strong in orthopedics, and they've got about 18,000 employees worldwide. They're listed on the New York Stock Exchange. Um, so they are fairly very credible partner that we've managed to engage. Yeah. How did that come about then?

0:57

Uh, it's a process, as you know, with, uh, working with these, uh, very large partners. And we are very excited to bring this process to a close, which means we get to ink the deal and start to work on, uh, further commercializing the craniofacial products that we have. Yeah. Okay. And so Zimmer is going to be distributing distributing these. Is it exclusive. You know will you be able to put more of these deals in place.

1:25

Um, it is an exclusive arrangement that we have with Zimmer. And um, looking for more deals. I think we, we as a company, we're always looking to refresh our distribution lineup. Uh, we're always looking for opportunities to expand and grow and accelerate accelerated rate. Uh, we strongly believe in the company's technology and the products, so we are fairly confident in creating more opportunities for such engagements. Yeah. Okay. And just to be clear, just for the investors and viewers watching it is technology that is used in dental primarily. Is that correct?

2:02

Um, primarily used in craniofacial reconstruction. So neurosurgical applications, um plastic surgery applications. So that's that's where we're at.

2:12

Yeah. Okay. And, um, you've got sort of a number then of different technologies that you're looking to commercialize. So just tell us where we're at in terms of, you know, the journey milestones that have been hit for some of some of these main products. Yep. So, um, the company is organized into four business areas. So there's craniofacial reconstruction. there's aesthetics, there's dental, and there is also orthopedic applications. So in the recent few months, we have gradually been progressing on some of the more nascent business units, such as orthopedics. We've gotten our Singapore and Vietnamese approvals. We are in the early stages of the commercialization process there. Uh, what has brought the company so far in a very stable and, um, reliable manner revenue wise, is the combination of the craniofacial reconstruction market as well as the aesthetic rhinoplasty market.

3:07

Yeah, you've been doing a lot. It's actually really interesting to read through some of your announcements to the ASX. So revenue growth is continuing. Is it? I think you have seen about 5% growth quarter on quarter. And do you need to raise further capital to hit your next milestones?

3:28

Um, we've seen about five quarters of growth, consecutive quarters. Um, and depending on the percentage. So some some quarters are larger than others. Uh, we we do look forward to continuing this revenue growth trend. Uh, of course it's pending some of our latest quarterly as well. Uh, in terms of raising capital. I think that has always been a constant discussion, and it's also part of the plan for us to make sure that we strengthen the books and put us in the best position to be very aggressive. As a regenerative medicine leader in this particular space. Okay. What market are you most focused on or what what is the, you know, the Holy grail when it comes to getting your products in the hands of practitioners?

4:14

Uh, for now, there's a very strong historical focus in Asia Pacific. But with the Zimmer agreement in place. It allows us to focus a little bit more into the European, Middle East and African markets, as well as Australia and New Zealand. So that should lead us, um, well into the future.

4:31

Um, in terms of getting practitioners on board. I think we always are focused on the very few, uh, the few large, uh, you know, very, uh, very focused markets in, for example, in the US, for example, in China. So there are still some steps for us to take in those countries. But we are working hard, uh, trying to deliver as much as we can. Uh, in terms of the company's growth, adoption of products and also delivering value to the shareholders. Why do you think, though, that the share price is lagging so much, Eugene? You know, you're obviously doing a lot of work, you know, really believe in the product. What is the market missing?

5:10

Uh, I think it, uh, I wouldn't say the market is missing, so to speak, but I think it takes a bit of time for us to really understand. And it's also a communication from us to the shareholders to make sure we are clear about how the company intends to operate. How we intend to bring the company forward and utilizing the platform technology that we have. How do we develop great products of high quality that would drive adoption and eventually revenue growth? So I think that is something that we continuously massaging that message, and we look forward to more opportunities to share a little bit more in deeper, uh, in a deeper way about how the company operates.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy